Lonza Group looks to long-term growth as a global contract manufacturer

Lonza Group AG (ISIN CH0013841017) is a global provider of contract development and manufacturing services for the pharmaceutical and biotechnology sectors, supporting companies with complex production needs and specialized facilities.

The Switzerland-based company focuses on producing active pharmaceutical ingredients, biologics, and related products under long-term agreements with industry partners, offering capabilities that many drug developers choose to outsource.

Contract manufacturing and services

Lonza Group AG concentrates on contract manufacturing services that cover a wide range of chemical and biological products used in human and animal health, enabling pharmaceutical and biotech firms to rely on external capacity for highly regulated production processes.

The company operates production sites and service centers across multiple regions, providing support along different stages of the drug development and manufacturing cycle, from early-stage projects to commercial-scale supply.

Strategic position in global pharma supply chains

As a contract manufacturer, Lonza Group AG plays an important role in global health-care supply chains, supplying ingredients and components that are needed in therapies, vaccines, and other medical products.

The company’s business model is built around long-term relationships with pharmaceutical and biotech customers, with a focus on quality, compliance with regulatory standards, and reliable delivery of complex products.

Representative business area

One representative area of Lonza Group AG’s business is the development and manufacturing of active pharmaceutical ingredients and biologics under contract for external clients, where the company provides infrastructure, technical expertise, and regulatory support for production that must meet stringent quality standards.

Stock and listing

Lonza Group AG is listed on its home stock exchange, giving investors access to the company through equity markets in its domestic jurisdiction.

Shares reflect investor expectations about the company’s contract manufacturing activities, growth prospects in pharmaceuticals and biotechnology, and its ability to maintain strong customer relationships over time.